CompletedN/A

Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension

NCT07811713 · Northern Jiangsu People's Hospital

Closed to entry

Status

Not accepting participants

Not applicable

Phase

496

Target enrolment

—

Study sites

What it is testing

Summary

Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites). Laparoscopy splenectomy and azygoportal disconnection (LSD) is a minimally invasive surgery commonly used to treat bleeding from swollen veins in these patients, but its impact on kidney function recovery remains unclear. This study will review medical records of patients with liver cirrhosis and portal hypertension who underwent LSD at our hospital. We will measure kidney function using estimated glomerular filtration rate (eGFR) before surgery and at 3, 6, 9, and 12 months after surgery to evaluate changes over time. We will also examine whether factors such as fluid buildup in the abdomen (ascites) before surgery are associated with kidney function changes after LSD. The goal is to better understand how LSD affects kidney function in these patients and to identify factors that may predict kidney function recovery, which could help improve care for cirrhotic patients undergoing this surgery.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Serum Creatinine (Scr) Level
Measured over At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Estimated Glomerular Filtration Rate (eGFR)
Measured over At preoperative baseline, postoperative month 3, month 6, month 9, month 12

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion Criteria: 1. Age ≥18 years. 2. Diagnosis of liver cirrhosis with portal hypertension. 3. Underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at our institution. 4. Adequate preoperative and postoperative clinical and follow-up data for analysis. 5. Preoperative and postoperative eGFR data available at the specified time points (baseline, month 3, 6, 9, and 12). Exclusion Criteria: 1. Child-Pugh Class C liver cirrhosis. 2. Primary renal diseases (e.g., glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.). 3. Previous abdominal surgery that precluded safe laparoscopic splenectomy and azygoportal disconnection (LSD). 4. Severe cardiac, pulmonary, or cerebrovascular dysfunction; malignant tumors; or primary hematological disorders. 5. Hepatic encephalopathy or refractory ascites within 1 month before surgery. 6. Pregnancy or lactation. 7. Poor compliance or inability to complete follow-up.

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07811713 on ClinicalTrials.gov →

Last updated in the registry 2026-09-10. Registry records change; this page reflects the data build of 2026-09-24.

Where this trial sits

Substance

Indication

All 6 trials from Northern Jiangsu People's Hospital →